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http://www.biomedcentral.com/1471-2407/14/827RESEARCH ARTICLE Open AccessGender dimorphism and age of onset in
malignant peripheral nerve sheath tumor
preclinical models and human patients
Elizabeth Shurell1, Linh M Tran2, Jonathan Nakashima2, Kathleen B Smith2, Brenna M Tam2, Yunfeng Li2,
Sarah M Dry3,4, Noah Federman5, William D Tap6, Hong Wu2,3* and Fritz C Eilber1,2,3*Abstract
Background: Gender-based differences in disease onset in murine models of malignant peripheral nerve sheath
tumor (MPNST) and in patients with Neurofibromatosis type-1-(NF-1)-associated or spontaneous MPNST has not
been well studied.
Methods: Forty-three mGFAP-Cre+;Ptenloxp/+;LSL-K-rasG12D/+ mice were observed for tumor development and
evaluated for gender disparity in age of MPNST onset. Patient data from the prospectively collected UCLA sarcoma
database (1974–2011, n = 113 MPNST patients) and 39 published studies on MPNST patients (n = 916) were
analyzed for age of onset differences between sexes and between NF-1 and spontaneous MPNST patients.
Results: Our murine model showed gender-based differences in MPNST onset, with males developing MPNST
significantly earlier than females (142 vs. 162 days, p = 0.015). In the UCLA patient population, males also developed
MPNST earlier than females (median age 35 vs. 39.5 years, p = 0.048). Patients with NF-1-associated MPNST had
significantly earlier age of onset compared to spontaneous MPNST (median age 33 vs. 39 years, p = 0.007). However,
expanded analysis of 916 published MPNST cases revealed no significant age difference in MPNST onset between
males and females. Similar to the UCLA dataset, patients with NF-1 developed MPNST at a significantly younger age
than spontaneous MPNST patients (p < 0.0001, median age 28 vs. 41 years) and this disparity was maintained across
North American, European, and Asian populations.
Conclusions: Although our preclinical model and single-institution patient cohort show gender dimorphism in
MPNST onset, no significant gender disparity was detected in the larger MPNST patient meta-dataset. NF-1 patients
develop MPNST 13 years earlier than patients with spontaneous MPNST, with little geographical variance.
Keywords: MPNST, Neurofibromatosis, Meta-analysis, EpidemiologyBackground
The significance of gender as a fundamental variable to be
studied in the development and progression of disease has
been a long standing topic of interest [1]. Men and women
differ in their genetic milieu and environmental exposures,
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reproduction in any medium, provided the orprogression [2]. Epidemiologic studies of cancer patients
reveal significant discrepancies in cancer incidence be-
tween sexes beyond the typical sex-specific malignancies
[3]. For example, gastric, esophageal, brain, liver, head and
neck cancers, and non-Hodgkin’s lymphoma occur more
often in men than women [3-5].
Mesenchymal glioblastoma multiforme (GBM), which
is thought to stem from similar biomolecular pathways
as malignant peripheral nerve sheath tumors (MPNST)
including loss of neurofibromin (NF1) and TP53 func-
tion [6,7], also shows increased prevalence of disease in
men [8,9]. A murine model of GBM formation devel-
oped from NF1 deficient mice expressing a dominant-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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intrinsic sexual dimorphism in the malignant transform-
ation of astrocytes to GBM, regardless of hormones or
tumor environment [9].
However, gender differences in the development of
MPNSTs have not specifically been examined. MPNST
is an aggressive soft tissue sarcoma (STS) that accounts
for up to 10 percent of all STS [10-12]. It is often associ-
ated with the autosomal dominant syndrome of Neuro-
fibromatosis type 1 (NF-1), but arise sporadically as well.
MPNSTs carry a particularly poor prognosis, with a 5-
year survival of 15-45% in NF-1 patients compared to
43-75% for non-NF-1 patients [10,13-15].
Although not all gender-based disparities are felt to be
based on hormonal differences, there does appear to be
a notable association amongst neurofibromas (NF), be-
nign peripheral nerve sheath tumors that are a hallmark
of neurofibromatosis, and circulating hormone levels. In
NF-1 patients, MPNSTs are often found in the context
of a preexisting NF. Although MPNST is felt to more
commonly arise from epineural and perineural NFs such
as subcutaneous and plexiform NF, the subtype of der-
mal NF shows considerable hormone responsiveness.
Dermal NFs often appear at puberty, reportedly increase
in number and size during pregnancy, and may regress
after delivery, implicating a possible hormonal influence
on tumor growth [16-18]. It has even been suggested that
steroid hormones may be involved in the malignant trans-
formation of neurofibroma to MPNST [19]. Investigation
of Schwann cell–enriched xenografted NF-1 human der-
mal NF, plexiform NF, and MPNST samples demonstrated
that estrogen and progesterone significantly increased the
growth of MPNST in 100% and 66% of samples, respect-
ively, and also increased growth in 25% of dermal NF
tested. However, estrogen and progesterone decreased
growth in 25% of xenografted plexiform NF with no effect
in the remaining plexiform NF samples [20].
Recently, the development of animal models that re-
capitulate neurofibroma and MPNST development have
allowed for investigation into the mechanisms of tumor
development and malignant transformation [21-23].
Interestingly, the N-ethyl-N-nitrosurea (ENU)-induced
rat model and the Nf1−/+;Tp53−/+ cis (i.e. B6-NPcis)
mouse model have both shown males to develop MPNSTs
at an earlier age than females, even while accounting
for confounding factors such as parental gender in the B6-
NPcis model [21,24,25]. This further underscores the pos-
sibility of sex-specific differences in MPNSTage of onset.
To further extend these studies, we examined our genet-
ically engineered murine model of MPNST for gender
differences. To evaluate if this model had clinically trans-
latable findings, we conducted an analysis of MPNST
patients diagnosed and treated at the University of
California, Los Angeles (UCLA) and analyzed a meta-dataset of patients from 39 published clinical MPNST
studies. Our study focused on age of MPNST diagnosis, as
this data is consistently reported in the published MPNST
literature. Evaluation of the interval between NF onset
to MPNST development was not assessed, as this data is
not routinely recorded. The aims of this study were to
evaluate gender dimorphism in MPNST age of onset
in the UCLA patient population and in a larger dataset
across several geographical populations, and to evaluate
differences in age of MPNST onset between NF-1 and
spontaneous patients.
Methods
Animals
Forty-three mGFAP-Cre+;Ptenloxp/+;LSL-K-rasG12D/+ MPNST
mice were generated as previously described [21]. These
mice develop multiple NFs with subsequent progression
to MPNST at a reproducible rate with 100% penetrance.
These mice were further purposed for MPNST chemo-
therapy studies (unpublished data), therefore non-invasive
methods of tumor detection were used. Given the small
tumor size at the time of detection, micro-PET/CT could
not reliably distinguish NF from MPNST based on SUV-
max (unpublished data), and was therefore not employed
in this study. Physical examination was performed daily to
detect tumor formation or illness. Mice were thoroughly
examined and palpated for tumor formation, which con-
sistently detected tumors as small as 4 mm diameter. We
previously showed that our murine model (Gregorian
et al. [19]) consistently progresses from neurofibroma to
MPNST two weeks after tumor onset, regardless of gen-
der. Therefore, initial time of palpable tumor development
was used as a surrogate for MPNST development. Mice
were euthanized per protocol if tumors reached a diameter
of 1.5 cm or interfered with feeding, grooming or ambula-
tion, or if the mouse lost >10% of their body weight. Sur-
vival times were not evaluated as the mice were purposed
for treatment studies (unpublished). Tumors were fixed
and embedded in paraffin, then sectioned and stained
with hematoxylin and eosin to confirm pathologic diagno-
sis of MPNST. Animals were housed in a temperature-,
humidity-, and light-controlled room (12-h light/dark
cycle), and allowed free access to food and water. All ex-
periments were conducted according to the research
guidelines of the University of California, Los Angeles
(UCLA) Chancellor’s Animal Research Committee.
UCLA data and patient selection
Since 1974, UCLA has prospectively maintained a sar-
coma database with complete clinical and pathologic pa-
tient data. A protocol detailing the study design and
analysis was approved by the UCLA Institutional Review
Board. For inclusion, subjects were required to have tis-
sue diagnosis of a MPNST and undergone surgery and
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study. Original surgical specimens were reviewed by a
UCLA sarcoma pathologist (S.M.D.) to re-confirm
pathologic diagnosis and grading.
External patient database
To validate our findings within a broader dataset, we
performed a PubMed search using the following algo-
rithm “(peripheral nerve sheath tumour[Title]) OR per-
ipheral nerve sheath tumor[Title]) OR MPNST[Title])
OR neurogenic sarcoma[Title]) OR malignant schwan-
noma[Title]) OR atypical neurofibromas[Title]) OR per-
ipheral nerve sheath tumors[Title]) OR peripheral nerve
sheath tumours[Title]) NOT case report[Title]” for pub-
lished articles from 1960–2011. For this study, only
references written in the English language were used.
Studies evaluating Neurofibromatosis type 2 were ex-
cluded. 990 hits were collected, and abstracts browsed to
identify relevant articles. The full manuscripts were
reviewed to identify studies that listed individual patients
with age of diagnosis, NF-1 status, gender, and geo-
graphic data. Ten PubMed suggested articles or citations
outside of our original search were included, and met
the above criteria. A total of 39 published studies with
data on 916 patients with MPNST was collected and ag-
gregated to form the meta-dataset (Additional file 1:
Table S1). Data was cross-referenced to ensure duplicate
patient reports were excluded. Patients were classified by
geographic location, gender, and NF-1 disease status for
subgroup analysis.
Statistical analysis
Statistical significance was determined using Wilcoxon
rank sum test, with a significance threshold of alpha
≤0.05. Variables assessed were age of diagnosis, gender,
and NF-1 status. Analysis of the datasets was performed
using STATA 12.0 (StataCorp. 2011) and R software
(R-package version 2.13).
Results
Genetically engineered murine model of MPNST
demonstrates gender dimorphism in disease onset
In our previous study, we developed a murine neuro-
fibroma model by conditional deletion of one allele of the
Pten tumor suppressor gene and activation of the K-rasG12D
oncogene in the Schwann progenitor cells (driven by
the mGFAP-Cre line) [21]. All neurofibroma lesions then
progress to MPNST with loss of heterozygosity of the
second allele of Pten and acquisition of high FDG-PET up-
take, reminiscent of human NF-to-MPNST malignant
transformation [21,26]. To examine whether MPNST onset
in this model is influenced by gender, we followed
43 mGFAP-Cre+;Ptenloxp/+;LSL-K-rasG12D/+ littermates, 24
males and 19 females, for MPNST development. Micedeveloped MPNST at a median time of 155 days. In the
context of gender-specific differences in tumor development,
a significant disparity in age of MPNST onset was iden-
tified. Male mice developed MPNST at a significantly
earlier age than female mice (142 versus 162 days,
respectively p = 0.015, see Figure 1). In the murine
ENU-induced MPNST model, genetic loci influential in
female specific resistance to MPNST development were
homologous to regions encoding estrogen receptors
(Additional file 1: Figure S1).
UCLA patients demonstrate gender dimorphism in age of
MPNST onset
The gender dimorphism observed in the rat and mouse
MPNST models prompted us to examine the age of
MPNST onset in our UCLA cohort of 113 unique
MPNST patients. The average age at initial MPNST
diagnosis was 40 years (median 38 years, range 16–94
years). Sixty-one patients (54%) were male, and 52 pa-
tients (46%) were female. Thirty patients (26%) devel-
oped MPNST in the context of NF-1, and 83 patients
(74%) developed MPNST spontaneously.
Evaluation of age of MPNST diagnosis by gender revealed
a trend toward males developing MPNST at an earlier age
than females (Figure 2; median age 35 years versus 39.5 years,
p = 0.048). Analysis of the NF-1-associated and spontaneous
MPNST patient populations individually revealed no statisti-
cally significant gender differences in age of MPNST onset
(p = 0.09 and p = 0.25, respectively). Interestingly, bimodal
distribution was observed in each subgroup (Figure 2), and
was most pronounced for female patients.
Meta-dataset fails to show gender dimorphism in MPNST
onset
To test whether the gender dimorphism observed in a
small cohort of UCLA patients could be confirmed in a
larger MPNST population, we conducted an analysis
based on publically available datasets. The meta-dataset
of patients with MPNST included North American,
European, and Asian populations; 916 total unique pa-
tients were identified. The overall median age at MPNST
diagnosis for men was 34 years (n = 451), compared to
the median age of 31 years in females (n = 465) however
this discrepancy was not significant (p = 0.26; See Table 1,
Figure 3A). Subgroup analysis between males and fe-
males in the NF-1 population and in the spontaneous
population showed no significant difference in age of
diagnosis (Figure 3A; p = 0.31 and p = 0.99, respectively).
NF-1 associated MPNST patients develop MPNST at a
significantly earlier age than spontaneous MPNST patients
Further analysis of the UCLA dataset revealed that
patients with NF-1-associated MPNST had a signifi-
cantly earlier age of onset compared to patients with
Figure 1 Gender dimorphism in age of MPNST onset in genetically engineered murine model. Female mice (black squares) developed
MPNST 20 days later than male mice (black circles) (p = 0.015). Gray line symbolizes median age of diagnosis for each cohort.
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39 years, p = 0.007). In the UCLA dataset, patients with
NF-1 developed MPNST an average of 10.3 years earlier
than patients without NF-1.
Similar to the UCLA dataset, the meta-dataset indi-
cated that patients with NF-1 developed MPNST at a
significantly younger age than patients without NF-1
(median 28 vs. 41 years old, p < 0.0001). Evaluation of
the overall distribution of male and female age of onset
(Figure 3A) revealed distinct peaks for NF-1 associatedFigure 2 Gender disparity in age of MPNST initial diagnosis in UCLA c
patients are represented in red, female patients are represented in blue.MPNST onset, as compared to the more broad distribu-
tion seen in spontaneous MPNST diagnosis.
The data was then analyzed by geographical regions of
North America, Europe, and Asia. In the North American
population, the median age of NF-1 patient MPNST
diagnosis was 28 (n = 218) compared to the age of 40 in
spontaneous MPNST patients (n = 236) (Figure 3B). In
the European population, the median age of diagnosis in
NF-1 patients was 27.9 (n = 250) compared to the spon-
taneous MPNST patient age of 41 (n = 157) (Figure 3C).ohort. Dashed lines represent spontaneous MPNST cases. Male
Table 1 UCLA and meta-dataset analysis shows significantly earlier age of MPNST onset in NF-1 patients compared to
spontaneous MPNST patients
Dataset Disease Male median
age (n)
Female median
age (n)
Male vs. female Wilcox
p value
Overall median
age (n)
NF-1 vs. spont. Wilcox
p value
UCLA NF-1 31 yrs (19) 39 yrs (11) 0.09 33 yrs (30) 0.007
Spont. 37 yrs (42) 40 yrs (41) 0.25 39 yrs (83)
Others NF-1 29 yrs (230) 27 yrs (266) 0.11 28 yrs (496) <0.0001
Spont. 43 yrs (221) 39 yrs (199) 0.88 41 yrs (420)
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nosis; however the size of this cohort was considerably
smaller than the others. In Asian populations, the median
age of diagnosis in NF-1 patients was 33.5 years (n = 28),
compared to a median age of diagnosis of 45 years in the
spontaneous MPNST population (p = 0.23) (Figure 3D).
Discussion
Our genetically engineered murine model of MPNST
showed significant gender dimorphism in age of MPNST
onset. To see if this was clinically translatable, we investi-
gated gender differences in age of MPNST onset first in
our UCLA patient cohort and second in a larger meta-
analysis of 916 published MPNST patients. The distribu-
tion of MPNST age of onset in our UCLA patient cohortFigure 3 Age of MPNST diagnosis. Distribution of age at MPNST diagnos
(C) European cohort (D) Asian cohort. Spontaneous MPNST patients are de
depicted with a solid line. Males are represented in red, females are represmirrored the gender dimorphism found in our pre-clinical
model, with men diagnosed with MPNST at an earlier age,
however this finding was not reflected in the larger meta-
analysis. The interrogation of gender in our murine model
(castration, hormonal manipulation, etc.) was not pursued
further as it was not replicated in the larger patient meta-
dataset. The gender disparity in the UCLA patient popula-
tion is likely due to the relative rarity of MPNST, as our
MPNST patient population was relatively small (n = 113).
The limitation of this initial result underscores the need
for collaborative effort in the study of STS subtypes.
In rare cancers, such as sarcoma, collective pursuits of
clinical research should be encouraged to increase the
power and effect-size of the analysis. When our initial
result was tested in a larger “meta-dataset” cohort, weis in (A) all MPNST patients including UCLA (B) North American cohort
picted with a dashed line, NF-1 associated MPNST patients are
ented in blue.
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and gender-based differences were not observed.
Additionally, recent literature supports multidisciplin-
ary management of patients with STS at a nationally
recognized sarcoma center. Age of diagnosis is likely in-
fluenced by non-clinical factors such as adherence to
guidelines, referral pathways, and time to referral to a
sarcoma center, which were not analyzed in this study.
Earlier age of MPNST diagnosis is likely favored by
prompt referral to a sarcoma center, and should there-
fore be encouraged in patients with suspicious tumors.
Analysis of the meta-dataset from 39 published studies
on MPNST revealed a 13 year difference in median age
of diagnosis between NF-1 and spontaneous MPNST pa-
tients. Using a larger multinational meta-dataset of 916
patients, we were able to confirm the findings of earlier
reports on smaller cohorts [10,27]. Given the rarity
of MPNST, it is important to study clinicopathologic
disease characteristics in larger, adequately powered
cohorts when possible. The earlier reports of age of on-
set differences were based on geographically localized,
single-institutional, small populations whose results had
the potential to be skewed by institutional differences in
monitoring and diagnosis protocols [10,27]. The dispar-
ity in age of onset in our meta-dataset was maintained
in North American, European, and Asian populations.
In the combined meta-dataset, the age of onset for the
NF-1 associated MPNST patients was centered around a
distinct peak, which differed significantly from the broad
distribution of age at diagnosis for spontaneous cases
that spans decades. This wide variance in spontaneous
cases suggests that the underlying genetic cause of spon-
taneous MPNST formation may be the accumulation of
a wide assortment of genetic aberrations over time, in
contrast to NF-1 MPNST formation which may be due
to a few specific genetic mutations.
This disparity between NF-1 and spontaneous patients
may also reflect the earlier and increased frequency of
routine physical exams and surveillance for MPNSTs in
NF-1 patients. Clinical manifestations of malignant
transformation classically rely on reported symptoms of
new neurological deficits, rapid increase in size, change
in palpated density from soft to hard, and unremitting
pain. Patients with NF-1 and clinicians who treat them
are often aware of the 10% lifetime risk of MPNST, and
might be more apt to notice these changes. The malig-
nant transformation event, whereby a NF degenerates
into a MPNST, is distinct from the time at which a
patient is formally diagnosed with MPNST. The interval
between MPNST development and diagnosis can be
shortened with the use of FDG-PET, as it has emerged
as an accurate method to distinguish NF from MPNST
based on the glycolytic phenotype [26]. Using quantita-
tive SUVmax measurements, the gap in time betweenactual MPNST development and formal diagnosis can
be truncated.
Limitations of this study are ones inherent in studying
a rare disease. First, patient diagnosis from both our
UCLA and meta-datasets spans decades, covering a time
period in which the diagnostic tools for MPNST detec-
tion were greatly improved. Improved detection through
computerized tomography and magnetic resonance im-
aging has likely led to earlier detection of MPNST. How-
ever, for the same time period, this would affect patients
of either sex equally, and affect both NF-associated and
spontaneous MPNST patients equally. Second, there
may be reporting bias, as most datasets were from
surgically-resected patients only, and exclude patients
with biopsy-proved but unresectable MPNST.
This study focused on MPNST age of onset only, and
did not include analysis of clinical factors such as age of
NF-1 diagnosis or disease stage at MPNST diagnosis, due
to lack of data reporting in the majority of the studies used
in the meta-analysis. Patient gender may influence the
development and progression of MPNST, however reports
are conflicting. A recent analysis by Kolberg et al. [10],
found no survival advantage between males and females
(in 117 spontaneous patients and 62 NF-1 patients) [14].
However, a separate study by Ingham et al. [21] found a
significant difference in survival between male and female
MPNST patients, with men having worse survival (n = 52,
p = 0.05) [28]. Given these contradictory findings, any
gender-specific survival advantage remains to be deter-
mined, and should be investigated within a larger cohort.
Conclusion
In conclusion, the difference in age of onset between
MPNST formation in NF-1 associated cases and spon-
taneous cases is reflected in both the actual age of onset
and in the population age distribution. This suggests
that the two branches of MPNST development are likely
rooted in distinct and separate origins, influenced by dif-
ferent genetic and environmental factors.
Additional file
Additional file 1: Supplemental Materials. Figure S1. Genetic
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Table S1. External datasets used in this study [27,29-66].
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